The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the positive results of the COBRA trial (NCT03517137), a Phase II study investigating PET-response adapted treatment with brentuximab vedotin-containing regimens for advanced Hodgkin lymphoma (HL). The trial showed prolonged progression-free survival (PFS) compared to the ECHELON-1 trial (NCT01712490). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Takeda, Roche and Genmab, Celgene, Novartis; Consultancy: Takeda, Roche and Genmab, Celgene, Novartis, AbbVie, AstraZeneca, Janssen, Merck, F. Hoffmann-La Roche Ltd, Bristol Myers-Squibb, Genentech, Incyte; Honoraria: Takeda, Roche and Genmab, Celgene, AbbVie, AstraZeneca, Merck, F. Hoffmann-La Roche Ltd; Membership on an Entity’s Board of Directors or Advisory Committees: Takeda, Roche and Genmab, Celgene, AbbVie, AstraZeneca, Janssen, Merck, F. Hoffmann-La Roche Ltd.
